<SEC-DOCUMENT>0001558370-25-000095.txt : 20250110
<SEC-HEADER>0001558370-25-000095.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110072935
ACCESSION NUMBER:		0001558370-25-000095
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41429
		FILM NUMBER:		25520413

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pmn-20250110x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 1/10/2025 10:03:11 AM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: c9bfcc72-4615-490d-99e9-745f59d0d62d -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:pmn="http://promisneurosciences.com/20250110" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>PROMIS NEUROSCIENCES&#160;INC._January 10, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityCentralIndexKey" id="Tc_QagER-W0QkCSn0OddOL_TQ_2_1">0001374339</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:AmendmentFlag" id="Tc_KyJSdpEhk0G2NYMgOTlP3A_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="pmn-20250110.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-10</xbrli:startDate><xbrli:endDate>2025-01-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77b90c7_0971_4e54_8ac6_f306e87b79dc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:DocumentType" id="Narr_IPC2uhLUpkCNsBzAzw0kyA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_ABcr27x-CU6vkPDBmJUhHA"><b style="font-weight:bold;">January 10, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityRegistrantName" id="Narr_A_EgXoZ7qEedYLYfXAl81g"><b style="font-weight:bold;">PROMIS NEUROSCIENCES&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e55439ec_4149_45bb_94a7_b731a68919b0"></a><a id="Tc_sJIrBAeSQ02ynfSsFrXa_g_1_0"></a><a id="Tc_NxO8uJroZ0GovV72frzrbA_1_2"></a><a id="Tc_o4csEuL7TEWXnCFir7Qz1g_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_o4luWUp51kGIoWTsS_0jhA_0_0"><b style="font-weight:bold;">Canada</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityFileNumber" id="Tc_HaLf6kKoWUiZakxsdvhvVQ_0_2"><b style="font-weight:bold;">001-41429</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityTaxIdentificationNumber" id="Tc_JWal--KAVUe5VSOMP1CgNg_0_4"><b style="font-weight:bold;">98-0647155</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br/><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br/><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><br/><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a9c8a93d_1b94_4d35_b5da_4b20628eb38d"></a><a id="Tc_HJAON1C5UESpp7cNPvSaeA_1_0"></a><a id="Tc_QoNNq_lyBk-59c6ZlA66vg_2_0"></a><a id="Tc_2feKBvpnxEyeF4-SCV-4vg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityAddressAddressLine1" id="Narr_8QGQ66OByE2hdKRxgjjMHQ"><b style="font-weight:bold;">Suite&#160;200</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityAddressAddressLine2" id="Narr_7AVXqPavLEWmr3NTfvxDFQ"><b style="font-weight:bold;">1920 Yonge Street</b></ix:nonNumeric><b style="font-weight:bold;">, </b><br/><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityAddressCityOrTown" id="Narr_zPI3tVdosUS_GgBd10ID8g"><b style="font-weight:bold;">Toronto</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_jnuVZuMJLUu1PmDFcj9X1g"><b style="font-weight:bold;">Ontario</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:EntityAddressPostalZipCode" id="Tc_LD4DApNLVkq5e2bmT0t15w_1_4"><b style="font-weight:bold;">M4S 3E2</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive</b><br/><b style="font-weight:bold;">offices)</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:CityAreaCode" id="Narr_k_vzlBEP-kK6fR0CB68s2A"><b style="font-weight:bold;">416</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:LocalPhoneNumber" id="Narr_jhz2S43ze06ph8qUFZEK7A"><b style="font-weight:bold;">847-6898</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_zSk98o1zxkOjjsGK8eyaVA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_qGxt-qBQw0me6Apt2mUgJA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_z1WnBtt96U6jvusHn-rfJw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_b9-jp9fSREWL6L7kgkRKDQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_74d67a36_7a0d_41c9_8325_4889e2447f26"></a><a id="Tc_65azR14RnEmwwbE0Wx9Uxw_1_0"></a><a id="Tc_dp7xBVmn9U6v98hzDFimGQ_1_2"></a><a id="Tc_mpyQgjiAC0KAxEFl3ZYlPg_1_4"></a><a id="Tc_UzUE0t6DbUO6RyiIy88cmA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:17.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:2.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:17.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:middle;width:34.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:Security12bTitle" id="Tc_qUacCjcKjUeUdy5duUgNbg_2_0">Common Shares, no par value per share</ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" name="dei:TradingSymbol" id="Tc_I8Mf5sWIMkWMdY2tRNnpPA_2_2">PMN</ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">The <ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_-y6kSOEXU0-dXmDAqfo0Ow">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_Q_lkIvWCM0GzsWe87gIF7Q"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_eF0qYaD4O0yb72k4aiLxGA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 10, 2025, ProMIS Neurosciences Inc. (the &#8220;Company&#8221;) issued a press release (the &#8220;Press Release&#8221;) announcing the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic candidate, PMN310, in Alzheimer&#8217;s disease (&#8220;AD&#8221;). A copy of the press release is attached hereto as Exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8.01 Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On January 10, 2025, the Company issued the Press Release announcing the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic candidate, PMN310, in AD.  The ongoing Phase 1b PRECISE-AD trial will assess the safety, tolerability, and pharmacokinetics of PMN310 over 12 months of treatment in 100 patients with mild cognitive impairment due to AD (Stage 3 AD) or early AD (Stage 4 AD). The study will also evaluate key biomarkers and clinical measures of efficacy to gather data on PMN310&#8217;s therapeutic potential. Results from the recently completed Phase 1a study in healthy volunteers demonstrated a generally favorable safety and tolerability profile, with drug concentrations in cerebrospinal fluid supporting its potential for robust target engagement in patients with AD. The Company anticipates reporting certain interim data in the first half of 2026.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this Current Report on Form 8-K constitutes forward-looking statements and forward-looking information (collectively, &#8206;&#8206;&#8220;forward-looking information&#8221;) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the &#8206;use of forward-looking terminology such as &#8220;plans&#8221;, &#8220;excited to&#8221;, &#8220;targets&#8221;, &#8220;expects&#8221; or &#8220;does not expect&#8221;, &#8220;is expected&#8221;, &#8220;an opportunity exists&#8221;, &#8206;&#8206;&#8220;is positioned&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;assumes&#8221;, &#8220;anticipates&#8221; or &#8220;does not anticipate&#8221; or &#8220;believes&#8221;, or variations of such words and &#8206;phrases or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221;, &#8220;will&#8221; or &#8220;will be taken&#8221;, &#8220;occur&#8221; or &#8220;be &#8206;achieved&#8221;. In addition, any statements that refer to expectations, projections or other characterizations of future events or &#8206;circumstances contain forward-looking information. Specifically, this Current Report on Form 8-K contains forward-looking information relating to the Company&#8217;s plans and expectations for the Phase 1b study of PMN310. Statements containing forward-looking information are not historical facts but instead represent management's current &#8206;expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events &#8206;and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this Current Report on Form 8-K, are subject to &#8206;known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, &#8206;performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that clinical data from healthy volunteers may not be indicative of future results in patients, the Company&#8217;s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the &#8220;Risk Factors&#8221; section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2023 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">(d)&#160;Exhibits</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:87.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20250110xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">99.1</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20250110xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated January 10, 2025</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cbe18623_6a19_414e_944b_7a42f40d41ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROMIS NEUROSCIENCES&#160;INC.</b></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 10, 2025</p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:48.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neil Warma</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Neil Warma</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pmn-20250110xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 1/10/2025 10:03:07 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="pmn-20250110xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:42.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:125.98pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer&#8217;s Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CAMBRIDGE, Massachusetts &#8211; January 10, 2025 &#8211; </b><font style="font-size:11pt;">ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic candidate, </font><b style="font-size:11pt;font-weight:bold;">PMN310</b><font style="font-size:11pt;">, in Alzheimer&#8217;s disease (AD). </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">PMN310, a humanized IgG1 antibody, is engineered to selectively target toxic oligomers of amyloid-beta (A&#946;O)&#8212;which are believed to be a key driver of Alzheimer&#8217;s pathology&#8212;while avoiding interaction with plaque deposits. This mechanism is designed to help reduce the risk of amyloid-related imaging abnormalities (ARIA), a common side effect associated with existing therapies, potentially offering a differentiated product profile. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">The ongoing Phase 1b PRECISE-AD trial will assess the safety, tolerability, and pharmacokinetics of PMN310 over 12 months of treatment in 100 patients with mild cognitive impairment (MCI) due to AD (Stage 3 AD) or early AD (Stage 4 AD). The study will also evaluate key biomarkers and clinical measures of efficacy to gather data on PMN310&#8217;s therapeutic potential. Results from the recently completed Phase 1a study in healthy volunteers demonstrated a generally favorable safety and tolerability profile, with drug concentrations in cerebrospinal fluid supporting its potential for robust target engagement in patients with AD.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">&#8220;The initiation of the PRECISE-AD trial is a major milestone in our journey to develop PMN310 as a potential treatment for AD,&#8221; said Neil Warma, CEO of ProMIS Neurosciences. &#8220;Current AD treatments offer only modest efficacy, often accompanied by significant side effect challenges such as ARIA, leaving a substantial unmet need for new options. We believe PMN310 has the potential to deliver on this need through its selective targeting mechanism.&#8221; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">&#8220;We have partnered with some of the best AD treatment centers in the U.S. for this trial and they are actively screening and enrolling patients. The PRECISE-AD trial has been carefully designed to generate robust clinical data, including biomarker insights and efficacy signals that will guide the next phase of development. We are excited about the opportunity to deliver real innovation to patients and look forward to sharing updates as we progress, with certain interim data anticipated in the first half of 2026.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">&#8220;Flourish Research is excited to partner with ProMIS Neurosciences on the&#160;research and&#160;development of their novel medication PMN310,&#8221; said Cameron S. Olezene, M.D., Principal Investigator at Flourish Research in Philadelphia, one of the first sites to become activated in the PRECISE-AD trial.&#160; </font><font style="font-size:11pt;">&#8220;Monoclonal antibodies targeting toxic amyloid-beta species are the first treatments that have shown disease modifying capacity for Alzheimer&#39;s disease.&#160;It is often preferable to have multiple therapeutics available as treatment options. Thus,&#160;PMN310 is exciting because&#160;of its novel targeting of amyloid oligomers,&#160;potentially offering another solution for physicians and their patients.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Mr. Warma added &#8220;the trial name, </font><b style="font-size:11pt;font-weight:bold;">PRECISE-AD,</b><font style="font-size:11pt;"> was chosen to reflect our focus on </font><b style="font-size:11pt;font-weight:bold;">P</b><font style="font-size:11pt;">ersonalized, </font><b style="font-size:11pt;font-weight:bold;">R</b><font style="font-size:11pt;">obust, and </font><b style="font-size:11pt;font-weight:bold;">E</b><font style="font-size:11pt;">ffective </font><b style="font-size:11pt;font-weight:bold;">C</b><font style="font-size:11pt;">linical </font><b style="font-size:11pt;font-weight:bold;">I</b><font style="font-size:11pt;">ntervention with </font><b style="font-size:11pt;font-weight:bold;">S</b><font style="font-size:11pt;">pecificity and </font><b style="font-size:11pt;font-weight:bold;">E</b><font style="font-size:11pt;">xcellence in addressing </font><b style="font-size:11pt;font-weight:bold;">A</b><font style="font-size:11pt;">lzheimer&#8217;s </font><b style="font-size:11pt;font-weight:bold;">D</b><font style="font-size:11pt;">isease. This name underscores our commitment to precision therapies, leveraging advanced science to selectively target the root causes of AD and deliver meaningful outcomes for patients. It also reflects the goal of the study design, which is to demonstrate PRECISE targeting of toxic oligomers by PMN310 in Alzheimer&#8217;s disease.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">The Phase 1b clinical trial (</font><font style="font-size:11pt;">NCT06750432</font><font style="font-size:11pt;">) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Stage 3 and Stage 4 AD.</font><font style="color:#c00000;font-size:11pt;"> </font><font style="font-size:11pt;">The study plans to enroll approximately 100 subjects across 22 active sites in the United </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="pmn-20250110xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:42.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:125.98pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">States. Eligible patients will be dosed monthly at one of the three dose levels or placebo over 12 months with assessment of safety, tolerability, PK, and pharmacodynamic blood- and brain-based markers of treatment effect at baseline and every three months. Frequent MRI scans throughout the study will be conducted to monitor for emergence of ARIA.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">About PMN310</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">PMN310 is a humanized monoclonal antibody (mAb) designed and developed based on its selectivity for soluble amyloid-beta oligomers (A&#946;Os), which are believed to be the most toxic and pathogenic form of A&#946;, relative to A&#946; monomers and amyloid plaques. Soluble A&#946;Os have been observed to be potent neurotoxins that bind to neurons, impair synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A&#946;Os, PMN310 aims to directly address the growing body of evidence indicating they may be the primary underlying cause of the neurodegenerative process in Alzheimer&#8217;s disease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">PMN310 has successfully completed a Phase 1a clinical study (</font><font style="font-size:11pt;">NCT06105528</font><font style="font-size:11pt;">), a double-blind, placebo-controlled, single ascending dose study of the safety, tolerability and pharmacokinetics of PMN310 infusions in healthy volunteers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">About ProMIS Neurosciences Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer&#8217;s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company&#8217;s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS&#8482; and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company&#8217;s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic A&#946; oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and, to date, PMN310 appears to selectively bind oligomers. ProMIS successfully completed a Phase 1a clinical study with PMN310 in healthy volunteers and has initiated a Phase 1b clinical trial in AD patients. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Nasdaq has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, &#8206;&#8206;&#8220;forward-looking information&#8221;) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the &#8206;use of forward-looking terminology such as &#8220;plans&#8221;, &#8220;targets&#8221;, &#8220;expects&#8221; or &#8220;does not expect&#8221;, &#8220;is expected&#8221;, &#8220;excited about&#8221;, &#8220;an opportunity exists&#8221;, &#8206;&#8206;&#8220;is positioned&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;assumes&#8221;, &#8220;anticipates&#8221; or &#8220;does not anticipate&#8221; or &#8220;believes&#8221;, or variations of such words and &#8206;phrases or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221;, &#8220;will&#8221; or &#8220;will be taken&#8221;, &#8220;occur&#8221; or &#8220;be &#8206;achieved&#8221;. In addition, any statements that refer to expectations, projections or other characterizations of future events or &#8206;circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the &#160;Company&#8217;s plans and expectations for the Phase 1b study of PMN310 , the potential for PMN310 to positively benefit patients with AD, the targeting of toxic misfolded proteins in neurodegenerative diseases that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of A&#946; are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity, the potential for PMN310&#8217;s mechanism of action to reduce the risk of amyloid-related imaging abnormalities (ARIA), management&#8217;s belief that its patented platform technology has created an antibody candidate specific to toxic misfolded oligomers known to be present in AD, therapeutic activity and preferential targeting of toxic soluble aggregates by A&#223;-directed antibodies and the potential implications thereof, the Company&#8217;s pipeline, including application of its platform to other diseases, . Statements containing forward-looking information are not historical facts but instead represent management&#39;s current &#8206;expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events &#8206;and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to &#8206;known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, &#8206;performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that clinical data from healthy volunteers may not be indicative of future </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="pmn-20250110xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:42.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:125.98pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">results in patients, risks related to progressing the Company&#8217;s Phase 1b trial and the Company&#8217;s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the &#8220;Risk Factors&#8221; section of the Company&#39;s most recently filed Annual Report on Form 10-K for the year ended December 31, 2023 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">For further information:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Visit us at </font><font style="font-size:11pt;">www.promisneurosciences.com</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Please submit media inquiries to </font><font style="font-size:11pt;">info@promisneurosciences.com</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">For Investor Relations, please contact: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Precision AQ (formerly Stern IR)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Anne Marie Fields, Managing Director</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">annemarie.fields@precisionaq.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Tel. 212-362-1200</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pmn-20250110xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20250110xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Y *@# 2(  A$! Q$!_\0
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pmn-20250110.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 10:03:16 AM-->
<!--Modified on: 1/10/2025 10:03:16 AM-->
<xsd:schema targetNamespace="http://promisneurosciences.com/20250110" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:pmn="http://promisneurosciences.com/20250110" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20250110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20250110_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20250110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>pmn-20250110_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 10:03:16 AM-->
<!--Modified on: 1/10/2025 10:03:16 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="pmn-20250110.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>pmn-20250110_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 10:03:16 AM-->
<!--Modified on: 1/10/2025 10:03:16 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>pmn-20250110_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 10:03:16 AM-->
<!--Modified on: 1/10/2025 10:03:16 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pmn-20250110.xsd#DocumentDocumentAndEntityInformation" roleURI="http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638721001968722836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638721001968722836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638721001968722836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638721001968722836" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638721001968722836" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638721001968722836" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638721001968722836" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638721001968722836" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638721001968722836" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638721001968722836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638721001968722836" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638721001968732825" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638721001968732825" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638721001968732825" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_638721001968732825" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_638721001968732825" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638721001968732825" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638721001968732825" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638721001968732825" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638721001968732825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638721001968732825" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638721001968742816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638721001968742816" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638721001968742816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638721001968742816" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638721001968742816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638721001968742816" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638721001968742816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638721001968742816" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638721001968742816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638721001968742816" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45911662347296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROMIS NEUROSCIENCES&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0647155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite&#160;200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">1920 Yonge Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Toronto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">ON<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">M4S 3E2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">847-6898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PMN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001374339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%9\7BH*627ZD7TJM99Q?;A@%#S,5X/E*2GTLF*\$Y4>>P;]02P,$%     @
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
ML3LJ6@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "Q.RI: L&2ONX    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "Q.RI:F5R<(Q &
M  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( +$[*EI6[PXUB 0  / 1   8              " @0T(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "Q.RI:GZ ;\+$"
M  #B#   #0              @ '+#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( +$[*EJ7BKL<P    !,"   +              "  :</  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( +$[*EH<.&7J/P$  #P"   /              "
M 9 0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "Q.RI:)!Z;HJT   #X
M 0  &@              @ '\$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "Q.RI:99!YDAD!  #/ P  $P              @ 'A
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   K%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pmn-20250110x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pmn-20250110.xsd</File>
    <File>pmn-20250110_def.xml</File>
    <File>pmn-20250110_lab.xml</File>
    <File>pmn-20250110_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="pmn-20250110x8k.htm">pmn-20250110x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pmn-20250110x8k.htm": {
   "nsprefix": "pmn",
   "nsuri": "http://promisneurosciences.com/20250110",
   "dts": {
    "schema": {
     "local": [
      "pmn-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "pmn-20250110_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pmn-20250110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pmn-20250110_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "pmn-20250110x8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20250110x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20250110x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-25-000095-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-000095-xbrl.zip
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MFX7VD3VJ3L#6572$:GLU1:^KE<HN=7OU;1<Y.;#*[8V2[%PI)W\!4$L#!!0
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M&0VMDZ(M'P35&;,MD3[.!:]? AZ:H.'42+AEA: D\Z=D6E,^%%FVX.522%4
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M-P0N]H$AZ'+AT",^,Y@SM"U&+%[P/\"%'B- J2(4<E]P9QHKD_UGSW,PKJ_
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M0/B[N28GT'.<&GTO@#MW.WB>C0,[/.0U!]X0P'L+X+F+I"XC)M784AT@LAC
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M4IBALW%L9!O745U=&'-@'V<1;DL*Y5H@Z0Q=RL-L-Q3\4'\CNTMYI OBPP^
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M:%MP"I"P Q=F]2!F]=!DAO<Y*2!YY6'60&?+4G 0TTHMXG8D=1ATN6@&PC2
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MY(F#B[AAS 2VV,3:)""$"[?@\\/L@R\_S?53K#>%@VG$L#&K# .N$.C%2I,
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M):H52^G6\CU<GLU(&RLM8UO7-A=:%@NXBJW-X&?HF\:G_P=02P,$%     @
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M#VXNS:@&1J^<"2,9+J8WUX_I1G J#HN"]GBFB!ODY]\0]!H-^[\V@=$2<BZ
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MV)]^B]9MH?]C_WMI'_.OM?T_4$L! A0#%     @ L3LJ6KK756/? P  T0\
M !               ( !     '!M;BTR,#(U,#$Q,"YX<V102P$"% ,4
M" "Q.RI:&R-C"? "   Y"P  %               @ $-!   <&UN+3(P,C4P
M,3$P7V1E9BYX;6Q02P$"% ,4    " "Q.RI:F&QOX? %  #T10  %
M        @ $O!P  <&UN+3(P,C4P,3$P7VQA8BYX;6Q02P$"% ,4    " "Q
M.RI:1\R:)+$$   _+@  %               @ %1#0  <&UN+3(P,C4P,3$P
M7W!R92YX;6Q02P$"% ,4    " "Q.RI:X,8%%>L:   $G@  $P
M    @ $T$@  <&UN+3(P,C4P,3$P>#AK+FAT;5!+ 0(4 Q0    ( +$[*EK[
M!D59_Q0  %=7   7              "  5 M  !P;6XM,C R-3 Q,3!X97@Y
=.60Q+FAT;5!+!08     !@ & (H!  "$0@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>pmn-20250110x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pmn-20250110.xsd" xlink:type="simple"/>
    <context id="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_QagER-W0QkCSn0OddOL_TQ_2_1">0001374339</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_KyJSdpEhk0G2NYMgOTlP3A_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_IPC2uhLUpkCNsBzAzw0kyA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_ABcr27x-CU6vkPDBmJUhHA">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_A_EgXoZ7qEedYLYfXAl81g">PROMIS NEUROSCIENCES&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_o4luWUp51kGIoWTsS_0jhA_0_0">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_HaLf6kKoWUiZakxsdvhvVQ_0_2">001-41429</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_JWal--KAVUe5VSOMP1CgNg_0_4">98-0647155</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_8QGQ66OByE2hdKRxgjjMHQ">Suite&#160;200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_7AVXqPavLEWmr3NTfvxDFQ">1920 Yonge Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_zPI3tVdosUS_GgBd10ID8g">Toronto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_jnuVZuMJLUu1PmDFcj9X1g">ON</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_LD4DApNLVkq5e2bmT0t15w_1_4">M4S 3E2</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_k_vzlBEP-kK6fR0CB68s2A">416</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_jhz2S43ze06ph8qUFZEK7A">847-6898</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_zSk98o1zxkOjjsGK8eyaVA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_qGxt-qBQw0me6Apt2mUgJA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_z1WnBtt96U6jvusHn-rfJw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_b9-jp9fSREWL6L7kgkRKDQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_qUacCjcKjUeUdy5duUgNbg_2_0">Common Shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Tc_I8Mf5sWIMkWMdY2tRNnpPA_2_2">PMN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_-y6kSOEXU0-dXmDAqfo0Ow">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_Q_lkIvWCM0GzsWe87gIF7Q">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_10_2025_To_1_10_2025_L81uwPuDoUSQaGPKTTe72Q"
      id="Narr_eF0qYaD4O0yb72k4aiLxGA">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
